Amryt Pharma plc
Director/PDMR Shareholding
The following notification is made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Ray Stafford
2
Reason for the notification
a)
Position/status
Chairman
b)
Initial Notification Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Amryt Pharma plc
b)
LEI
213800YNUJEOJ8L4T95
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument,
type of
instrument
Identification code
Ordinary shares of £0.06 each
GB00BKLTQ412
b)
Nature of the transaction
Purchase of Shares
c)
Price(s) and volume(s)
Price(s) | Volume(s) |
£2.00 | 300,100 ordinary shares |
d)
Aggregated information
— Aggregated volume
— Price
N/A – single transaction
e)
Date of the transaction
March 12, 2021
f)
Place of the transaction
London Stock Exchange, AIM
Contacts Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200, ir@amrytpharma.com Edward Mansfield, Shore Capital, NOMAD, +44 (0) 207 468 7906, edward.mansfield@shorecap.co.uk Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564, tim@lifesciadvisors.com Amber Fennell, Consilium Strategic Communications, +44 (0) 203 709 5700, fennell@consilium-comms.com |